Stroke
Conditions
Brief summary
The primary endpoint is the difference in mean or median change in inflammatory biomarker panel from baseline to end of treatment
Detailed description
The secondary endpoint is the proportion of patients at the end of treatment whose hsCRP level is suppressed below 2mg/L. Description of changes in inflammatory markers after treatment will also be a secondary analysis. Secondary endpoints will also include proportion of patients who discontinue colchicine treatment due to poor tolerability and prevalence of adverse events associated with colchicine treatment.
Interventions
Sponsors
University College Dublin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the difference in mean or median change in inflammatory biomarker panel from baseline to end of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is the proportion of patients at the end of treatment whose hsCRP level is suppressed below 2mg/L. Description of changes in inflammatory markers after treatment will also be a secondary analysis. Secondary endpoints will also include proportion of patients who discontinue colchicine treatment due to poor tolerability and prevalence of adverse events associated with colchicine treatment. | — |
Countries
Ireland
Outcome results
None listed